Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALT NASDAQ:KOD NASDAQ:RARE NASDAQ:TRVI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$2.71-7.2%$3.07$2.56▼$7.73$567.86M0.212.62 million shs3.12 million shsKODKodiak Sciences$31.05-9.1%$39.76$3.43▼$47.84$2.14B2.21638,104 shs1.45 million shsRAREUltragenyx Pharmaceutical$21.91-6.0%$23.69$18.29▼$42.37$2.30B0.371.50 million shs1.12 million shsTRVITrevi Therapeutics$13.33-4.3%$13.76$5.41▼$16.12$1.98B1.041.11 million shs729,271 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune+1.92%-4.89%-4.58%-17.51%-46.81%KODKodiak Sciences+0.86%-5.43%-19.92%+37.41%+760.45%RAREUltragenyx Pharmaceutical+4.02%+0.21%-6.80%+9.69%-36.33%TRVITrevi Therapeutics+3.57%-3.60%-4.98%+4.74%+111.70%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$2.71-7.2%$3.07$2.56▼$7.73$567.86M0.212.62 million shs3.12 million shsKODKodiak Sciences$31.05-9.1%$39.76$3.43▼$47.84$2.14B2.21638,104 shs1.45 million shsRAREUltragenyx Pharmaceutical$21.91-6.0%$23.69$18.29▼$42.37$2.30B0.371.50 million shs1.12 million shsTRVITrevi Therapeutics$13.33-4.3%$13.76$5.41▼$16.12$1.98B1.041.11 million shs729,271 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune+1.92%-4.89%-4.58%-17.51%-46.81%KODKodiak Sciences+0.86%-5.43%-19.92%+37.41%+760.45%RAREUltragenyx Pharmaceutical+4.02%+0.21%-6.80%+9.69%-36.33%TRVITrevi Therapeutics+3.57%-3.60%-4.98%+4.74%+111.70%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 2.50Moderate Buy$16.67515.01% UpsideKODKodiak Sciences 2.63Moderate Buy$42.1435.73% UpsideRAREUltragenyx Pharmaceutical 2.82Moderate Buy$59.56171.85% UpsideTRVITrevi Therapeutics 3.00Buy$22.9071.79% UpsideCurrent Analyst Ratings BreakdownLatest ALT, RARE, KOD, and TRVI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2026ALTAltimmune CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/21/2026RAREUltragenyx Pharmaceutical Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$84.00 ➝ $96.005/20/2026TRVITrevi Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.005/18/2026ALTAltimmune HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.00 ➝ $20.005/14/2026ALTAltimmune Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$14.00 ➝ $11.005/11/2026KODKodiak Sciences Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$14.00 ➝ $61.005/8/2026RAREUltragenyx Pharmaceutical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/8/2026TRVITrevi Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$30.005/8/2026RAREUltragenyx Pharmaceutical GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$52.00 ➝ $43.005/6/2026TRVITrevi Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$20.005/6/2026RAREUltragenyx Pharmaceutical Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$45.00 ➝ $47.00(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$36K14,639.57N/AN/A$1.99 per share1.36KODKodiak SciencesN/AN/AN/AN/A$2.97 per shareN/ARAREUltragenyx Pharmaceutical$670M3.22N/AN/A($0.83) per share-26.40TRVITrevi TherapeuticsN/AN/AN/AN/A$1.43 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.09M-$0.93N/AN/AN/A-214,860.98%-42.57%-35.57%8/11/2026 (Estimated)KODKodiak Sciences-$229.97M-$4.17N/AN/AN/AN/A-253.85%-81.48%8/12/2026 (Estimated)RAREUltragenyx Pharmaceutical-$575M-$6.11N/AN/AN/A-91.03%-1,024.42%-45.78%8/4/2026 (Estimated)TRVITrevi Therapeutics-$42.76M-$0.32N/AN/AN/AN/A-24.53%-23.37%8/6/2026 (Estimated)Latest ALT, RARE, KOD, and TRVI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ALTAltimmune-$0.25-$0.18+$0.07-$0.18$0.00 millionN/A5/7/2026Q4 2025KODKodiak Sciences-$0.93-$0.94-$0.01-$0.94N/AN/A5/5/2026Q1 2026RAREUltragenyx Pharmaceutical-$1.4878-$1.84-$0.3522-$1.84$158.19 million$136.00 million5/5/2026Q1 2026TRVITrevi Therapeutics-$0.07-$0.09-$0.02-$0.09N/AN/A3/31/2026Q4 2025KODKodiak Sciences-$1.02-$1.04-$0.02-$1.04N/AN/A3/17/2026Q4 2025TRVITrevi Therapeutics-$0.10-$0.06+$0.04-$0.06N/AN/A3/5/2026Q4 2025ALTAltimmune-$0.25-$0.2719-$0.0219-$0.27$0.00 million$0.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/ATRVITrevi TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmune0.1229.5629.56KODKodiak SciencesN/A3.543.54RAREUltragenyx PharmaceuticalN/A2.021.85TRVITrevi TherapeuticsN/A24.7524.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%KODKodiak Sciences89.06%RAREUltragenyx Pharmaceutical97.67%TRVITrevi Therapeutics95.76%Insider OwnershipCompanyInsider OwnershipALTAltimmune1.60%KODKodiak Sciences45.90%RAREUltragenyx Pharmaceutical5.20%TRVITrevi Therapeutics18.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune50194.47 million191.36 millionOptionableKODKodiak Sciences9062.58 million33.86 millionOptionableRAREUltragenyx Pharmaceutical1,37198.49 million93.37 millionOptionableTRVITrevi Therapeutics20141.98 million116.00 millionOptionableALT, RARE, KOD, and TRVI HeadlinesRecent News About These CompaniesTrevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.June 4 at 6:07 PM | aol.comATrevi Therapeutics Shareholders Approve Stock and Governance ChangesJune 4 at 5:31 PM | tipranks.comTrevi Therapeutics, Inc. (TRVI) Analyst/Investor Day - SlideshowMay 15, 2026 | seekingalpha.comTrevi Therapeutics, Inc. (TRVI) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks TranscriptMay 12, 2026 | seekingalpha.comNan Fung Trinity HK Ltd. Boosts Holdings in Trevi Therapeutics, Inc. $TRVIMay 10, 2026 | marketbeat.comF m Investments LLC Buys New Position in Trevi Therapeutics, Inc. $TRVIMay 10, 2026 | marketbeat.comComerica Bank Has $1.04 Million Stake in Trevi Therapeutics, Inc. $TRVIMay 10, 2026 | marketbeat.comTrevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030May 9, 2026 | marketbeat.comTrevi Therapeutics (NASDAQ:TRVI) Stock Rating Lowered by Wall Street ZenMay 9, 2026 | marketbeat.comTrevi Therapeutics (TRVI) Gets a Buy from H.C. WainwrightMay 8, 2026 | theglobeandmail.comEquities Analysts Offer Predictions for TRVI Q2 EarningsMay 8, 2026 | marketbeat.comTrevi Therapeutics, Inc. (TRVI) Analyst/Investor Day TranscriptMay 7, 2026 | seekingalpha.comTrevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2026 Earnings Call TranscriptMay 7, 2026 | insidermonkey.comResearch Analysts Set Expectations for TRVI FY2030 EarningsMay 7, 2026 | marketbeat.comWhy Trevi Therapeutics (TRVI) Is Up 5.9% After Extending Its Cash Runway Into 2030May 6, 2026 | finance.yahoo.comTrevi Therapeutics (NASDAQ:TRVI) Price Target Lowered to $23.00 at Needham & Company LLCMay 6, 2026 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Trevi Therapeutics (NASDAQ:TRVI)May 6, 2026 | marketbeat.comTrevi Therapeutics, Inc. (TRVI) Q1 2026 Earnings Call TranscriptMay 6, 2026 | seekingalpha.comTrevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdatesMay 5, 2026 | globenewswire.comTrevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International ConferenceApril 30, 2026 | globenewswire.comTrevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026April 28, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesIonQ Just Posted a Breakout Quarter—But 1 Problem RemainsBy Nathan Reiff | May 7, 20263 Rare Earth Stocks That Win No Matter What China Does NextBy Bridget Bennett | May 24, 2026What the FDA's Latest Proposal Means for Lilly, Novo, and HimsBy Leo Miller | May 7, 2026Buffett Spent 60 Years Ignoring Tech and the Bill Is Coming DueBy Bridget Bennett | May 9, 2026Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in FocusBy Jessica Mitacek | May 8, 2026ALT, RARE, KOD, and TRVI Company DescriptionsAltimmune NASDAQ:ALT$2.71 -0.21 (-7.19%) Closing price 04:00 PM EasternExtended Trading$2.70 0.00 (-0.18%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Kodiak Sciences NASDAQ:KOD$31.05 -3.11 (-9.10%) Closing price 04:00 PM EasternExtended Trading$30.46 -0.60 (-1.92%) As of 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.Ultragenyx Pharmaceutical NASDAQ:RARE$21.91 -1.40 (-6.01%) Closing price 04:00 PM EasternExtended Trading$21.92 +0.00 (+0.02%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.Trevi Therapeutics NASDAQ:TRVI$13.33 -0.60 (-4.31%) Closing price 04:00 PM EasternExtended Trading$13.33 0.00 (0.00%) As of 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
